Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biotechnology

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

- PMLiVE

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

Seeks FDA approval to treat GVHD patients

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

- PMLiVE

AbbVie weak on new drug sales, but Humira stays strong

World’s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

Two new hepatitis C therapies fast-tracked in Europe

EMA speeds review process for Gilead and AbbVie treatments

- PMLiVE

Ashley Communications celebrates 20 years of medical communications

Looks forward with new business wins, including AbbVie and Merck & Co accounts

EU flag

EU clears AbbVie’s leukaemia drug venetoclax

Becomes the first BCL-2 inhibitor to be approved by the EMA

- PMLiVE

AbbVie’s ‘The Story of HS’ wins at PMEA 2016

Takes top prize in Excellence in Training Capability Development

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

- PMLiVE

Roche creates the Fight IPF choir for disease awareness campaign

Aims to raise the lung disease's profile and inform patients and their families

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links